ARTICLE | Clinical News

Nuplazid: Ph II started

November 17, 2016 2:33 PM UTC

Acadia began the double-blind, placebo-controlled, international Phase II ADVANCE trial to evaluate once-daily oral Nuplazid in combination with ongoing antipsychotic treatment for 26 weeks in about 3...

BCIQ Company Profiles

Acadia Pharmaceuticals Inc.

BCIQ Target Profiles

Serotonin (5-HT2A) receptor